Economic aspects of commercial manufacture of biopharmaceuticals

Journal of Biotechnology

Volumn 113, Issue 1-3, 2004, Pages 171-182

  Werner, Rolf G ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Biopharmaceutical; Expression host systems; Human antibodies; Process economics; Therapeutic proteins

Indexed keywords

BIOPHARMACEUTICALS; PRODUCT QUALITY; THERAPEUTIC DOSES;

ECONOMICS; INVESTMENTS; MARKETING; MONOCLONAL ANTIBODIES; PROTEINS;

DRUG PRODUCTS;

ABCIXIMAB; ADALIMUMAB; ALTEPLASE; BERTILIMUMAB; EDRECOLOMAB; GEMTUZUMAB OZOGAMICIN; GLYCOPEPTIDE; IBRITUMOMAB TIUXETAN; INFLIXIMAB; LERDELIMUMAB; MONOCLONAL ANTIBODY; NEURAMINIC ACID; ORTHOCLONE; PALIVIZUMAB; RESIN; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; BIOASSAY; BIOREACTOR; BIOTECHNOLOGICAL PRODUCTION; CAPITAL; CELL ADHESION; CELL DENSITY; CELL LINE; CLINICAL TRIAL; CONFERENCE PAPER; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG ACTIVITY; DRUG FORMULATION; DRUG MEGADOSE; DRUG SAFETY; ECONOMIC ASPECT; FERMENTATION; GENE CONSTRUCT; GLYCOSYLATION; HALF LIFE TIME; HOST CELL; HUMAN; LAW ENFORCEMENT; NONHUMAN; PHYSIOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUALITY CONTROL; STATISTICAL SIGNIFICANCE; VALIDATION PROCESS;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; BIOPHARMACEUTICS; BIOREACTORS; HUMANS; MOLECULAR SEQUENCE DATA; RECOMBINANT PROTEINS; TISSUE PLASMINOGEN ACTIVATOR;

GOES;

EID: 4544365911     PISSN: 01681656     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2004.04.036     Document Type: Conference Paper

References (17)

1. A.H. Bakker, E.F. Rehberg, K.R. Marotti, and J.H. Verheijen The position of the structurally autonomous kringle 2 domain influences the functional features of tissue-type plasminogen activator Protein Eng. 8 3 1995 293 300
2. D.T. Berg, P.J. Burck, D.H. Berg, and B.W. Grinnell Kringle glycosylation in a modified human tissue plasminogen activator improves functional properties Blood 81 5 1993 1312 1322
3. J.C. Costello, and P.B. Halverson A new era in rheumatoid arthritis treatment WMJ 102 7 2003 29 33 (review)
4. A.G. Finesilver Newer approaches to the treatment of rheumatoid arthritis WMJ 102 7 2003 34 37 (review)
5. A. Forero, and A.F. Lobuglio History of antibody therapy for non-Hodgkin's lymphoma Semin. Oncol. 30 6 Suppl. 17 2003 1 5 (review)
6. M.L. Gray, S. Khan, and R. Zimmerman Novel cancer therapies: targeting the molecules JAAPA 16 10 2003 24 27
7. B.M. Kumpel, T.W. Rademacher, G.A. Rook, P.J. Williams, and I.B. Wilson Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed B-lymphoblastoid cell-lines is dependent on culture method and affects Fc receptor-mediated functional activity Hum. Antibodies Hybridomas 5 3-4 1994 143 151
8. B.L. Maiorella, J. Winkelhake, J. Young, B. Moyer, R. Bauer, M. Hora, J. Andya, J. Thomson, T. Patel, and R. Parekh Effect of culture conditions on IgM antibody structure, pharmacokinetics and activity Biotechnology (NY) 11 3 1993 387 392
9. R.S. Senger, and M.N. Karim Effect of shear stress on intrinsic CHO culture state and glycosylation of recombinant tissue-type plasminogen activator protein Biotechnol. Prog. 19 4 2003 1199 1209
10. R. Sodoyer Expression systems for the production of recombinant pharmaceuticals BioDrugs 18 1 2004 51 62
11. M. Toi, M. Takada, H. Bando, K. Toyama, H. Yamashiro, S. Horiguchi, and S. Saji Current status of antibody therapy for breast cancer Breast Cancer 11 1 2004 10 14 (review)
12. Walter, J., Allgaier, H., 1997. Validation of downstream processes mammalian cell biotechnology in protein production, Walter de Gryter (offprint).
13. Werner, R.G., Noe, W., Kopp, K., Schlüter, M., 1998. Appropriate mammalian expression systems for biopharmaceuticals. Arzneimittelforschung/Drug Res. 48 (II), No. 8, 870-880.
14. Werner, R.G., 1998a.Value of contract manufacturing. Pharmaceutical Technol. Europe, October, Publication No. 0300.
15. Werner, R.G., 1998b. Economy of mammalian cell culture derived biopharmaceuticals. Med. Fac. Landbouww. Univ. Gent 63/4a.
16. Werner, R.G., 2001. Improving natural principles with genetic engineering: TNK-Tissue plasminogen activator. Arzneimittelforschung/Drug Res. 51 (I), No. 6, 516-520.
17. R.G. Werner Transgenic manufactured biopharmaceuticals: a new method of drug manufacturing Exp. Opin. Invest. Drugs 8 6 1999 731 736